| 4.40 Data as of May 17 |  +0.1199 / +2.80%Today’s Change | 3.60 Today|||52-Week Range 45.00 | -65.85% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $11.7M |
Company Description
Oxygen Biotherapeutics, Inc. is a development stage biomedical company, which is focused on developing oxygen-carrying intravenous and topical products. The company designs, develops and markets Dermacyte line of skin care products, which address several common aging issues, such as fine lines, wrinkles, puffiness, skin tone, blemishes and more. The company's Oxycyte PFC product, which is in Phase IIb clinical trials in Switzerland and Israel, is being developed for the traumatic brain injury. In addition, the company is developing a PFC-based topical cream for for dermatologic indications and wounds. Oxygen Biotherapeutics was founded on May 5, 1967 and is headquartered in Morrisville, NC.
Employees
Shareholders
| Other institutional | 1.66% |
| Individual stakeholders | 0.79% |
| Mutual fund holders | 0.46% |
Top Executives
| Michael B. Jebsen, CPA | President, Chief Executive & Financial Officer |
| Timothy Bradshaw, PhD | Executive Vice President-Clinical Development |
| Ellen T. Corliss | Vice President-Communications & Investor Relations |
| Nancy Hecox, MBA | Secretary, SVP-Legal Affairs & General Council |
.
